Compare PMTS & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | KRRO |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.4M | 150.0M |
| IPO Year | 2015 | 2019 |
| Metric | PMTS | KRRO |
|---|---|---|
| Price | $17.42 | $12.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $27.67 | ★ $34.80 |
| AVG Volume (30 Days) | 36.7K | ★ 144.5K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $312,189,000.00 | $6,392,000.00 |
| Revenue This Year | $9.95 | N/A |
| Revenue Next Year | $10.02 | N/A |
| P/E Ratio | $14.67 | ★ N/A |
| Revenue Growth | 12.27 | ★ 181.46 |
| 52 Week Low | $10.81 | $5.20 |
| 52 Week High | $27.31 | $55.89 |
| Indicator | PMTS | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 47.56 |
| Support Level | $13.01 | $12.51 |
| Resistance Level | $18.09 | $14.76 |
| Average True Range (ATR) | 1.04 | 0.77 |
| MACD | -0.13 | -0.19 |
| Stochastic Oscillator | 16.72 | 10.05 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.